Jomil (Tamsulosin Hydrochloride, Solifenacin Succinate)

Tamsulosin blocks alpha‑1 receptors in the prostate and bladder neck, relaxing smooth muscle and easing urine passage. Solifenacin blocks M3 muscarinic receptors in the bladder detrusor muscle, reducing involuntary contractions and urgency. Together they target the two main mechanisms that cause urinary obstruction and overactivity.

The appropriate dose of Jomil is determined by the prescribing healthcare professional based on the patient’s clinical condition, response, and any comorbidities. Dosage adjustments may be required for renal or hepatic impairment, and the prescriber will provide specific instructions.

Safety data for Jomil in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Jomil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

For BPH, tamsulosin alone is a common alpha‑blocker, while Jomil adds solifenacin to also address bladder overactivity. Compared with antimuscarinic monotherapy for OAB, Jomil provides the added benefit of relieving prostate‑related obstruction. The combination may reduce the need for multiple separate prescriptions but requires monitoring for combined side‑effects.

Jomil should be stored at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the tablet container tightly closed and out of reach of children.

Jomil is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water and follow any specific timing instructions provided by the healthcare professional.

Serious risks include severe hypotension or syncope, acute urinary retention, and rare allergic reactions such as rash, angioedema, or anaphylaxis. Patients should seek immediate medical attention if they experience fainting, inability to urinate, or signs of a severe allergic response.

Jomil is contraindicated in patients with known hypersensitivity to tamsulosin, solifenacin, or any excipients, as well as in individuals with severe urinary retention, uncontrolled narrow‑angle glaucoma, or those taking strong CYP3A4 inhibitors that could raise drug levels. Pregnant women should avoid use unless clearly indicated by a physician.